TMEM106B (Transmembrane Protein 106B) has emerged as a critical genetic modifier in frontotemporal dementia (FTD), particularly in individuals carrying pathogenic variants in the GRN (progranulin) gene[1]. This page synthesizes current knowledge of TMEM106B haplotypes, their mechanisms of action, and therapeutic implications.
TMEM106B is a lysosomal transmembrane protein encoded by the TMEM106B gene located on chromosome 7p21.3. It is highly expressed in the brain, particularly in microglia and neurons, and localizes to lysosomal membranes where it functions as an ion channel or transporter[2].
TMEM106B forms amyloid fibrils in human brains in an age-dependent manner[3], and these fibrils are found in frontotemporal lobar degeneration (FTLD)-TDP-43 brains[4]. The protein can form homotypic fibrils across diverse neurodegenerative diseases[5].
Genome-wide association studies (GWAS) identified a common variant at 7p21.3 (the TMEM106B locus) as associated with increased risk for FTLD with TDP-43 inclusions[1:1]. Subsequent research identified two major haplotypes:
The TMEM106B H2 haplotype (protective variant) is associated with:
The TMEM106B H1 haplotype (risk variant) is associated with:
TMEM106B haplotypes influence FTD pathogenesis through several molecular mechanisms:
| Factor | H1/H1 (Risk) | H2/H2 (Protective) |
|---|---|---|
| Age of Onset | ~5-10 years earlier | Later onset |
| Disease Severity | More severe | Milder phenotype |
| Brain Atrophy | Greater, especially frontal/temporal | Less atrophy |
| Survival | Shorter | Longer |
| CSF Progranulin | Lower levels | Higher levels |
While TMEM106B has been most extensively studied in GRN mutation carriers, emerging evidence suggests it may also modify disease in individuals with MAPT mutations:
TMEM106B haplotypes significantly influence TDP-43 pathology in FTD[^8]:
This section highlights recent publications relevant to this disease.
Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes. ↩︎ ↩︎
Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease. ↩︎ ↩︎
Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease. ↩︎
Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study. ↩︎
Truncation mutation of CHMP2B disrupts late endosome function but reduces TDP-43 aggregation through HSP70 upregulation. ↩︎